The US Enteric Softgel Capsules market is experiencing robust growth driven by advancements in pharmaceutical formulations and increasing demand for targeted drug delivery. The market, valued at USD 415 million in 2025, is expected to reach USD 865 million by 2035, registering a CAGR of 7.4% between 2024 and 2035. Major industry players such as Catalent, Inc., and Patheon (a Thermo Fisher Scientific company) are at the forefront of technological innovation and market expansion. Market trends are shaped by increasing investments in research and the integration of advanced technologies to improve efficacy and patient compliance.
The economic impact of tariffs on "US Enteric Softgel Capsules".
US Enteric Softgel Capsules Market Growth Drivers
Rising Prevalence of Gastrointestinal Disorders: The increasing incidence of gastrointestinal diseases such as inflammatory bowel disease (IBD) and Crohn’s disease has significantly fueled the demand for enteric softgel capsules that protect active ingredients from stomach acid, ensuring targeted release in the intestine. Major pharmaceutical companies like Catalent, Inc. have responded by expanding their product portfolios to include gastro-resistant formulations, addressing this growing need and enhancing patient outcomes.
Advancements in Encapsulation Technology: Technological innovations, such as improved coating materials and precise drug-release mechanisms, have driven market growth. Patheon, by Thermo Fisher Scientific, has heavily invested in state-of-the-art encapsulation processes, giving rise to a new generation of softgel capsules with improved stability and controlled release. These advances have not only broadened the application spectrum but also assured pharmaceutical manufacturers of regulatory compliance and better bioavailability.
US Enteric Softgel Capsules Market Trends
Expansion of Nutraceutical Applications: Increasing consumer emphasis on preventative healthcare and wellness has expanded the use of enteric softgel capsules in the nutraceuticals segment. For example, companies like Aenova Group are launching omega-3 and probiotic capsules with enteric coatings, providing extended product shelf life and enhanced effectiveness. This trend aligns with the growing preference for dietary supplements that offer targeted delivery and improved absorption.
Sustainability Initiatives and Green Manufacturing: Key market players are adopting eco-friendly practices by integrating biodegradable and plant-based capsule materials. Sirio Pharma, for instance, has launched plant-based enteric capsules to cater to vegetarian and vegan consumers and reduce the industry's environmental footprint. These efforts not only differentiate product lines but also meet stricter regulatory and consumer demands for sustainability in pharma manufacturing.
US Enteric Softgel Capsules Market Opportunity
Emergence of Biologics and Biosimilars: The rapid development of biologics and biosimilars presents significant opportunities for enteric softgel capsule manufacturers. Companies such as Capsugel (Lonza) are collaborating with biotech firms to develop innovative enteric delivery systems for sensitive biological drugs, enhancing therapeutic outcomes and expanding market reach.
Expansion into Pediatric and Geriatric Segments: Unique drug delivery challenges in pediatric and geriatric populations create opportunities for tailored enteric softgel formulations. Firms like Catalent are focusing research and development efforts on flavor-masked, easy-to-swallow, and customizable dosing options to address the needs of these demographic groups and increase adherence.
US Enteric Softgel Capsules Market Revenue (USD Million), 2020-2035
The generated chart highlights the steady increase of the US Enteric Softgel Capsules market over the forecast period. Beginning at USD 240 million in 2020, the market demonstrates consistent year-on-year growth, reaching USD 415 million by 2025. This upward trend is expected to continue, with revenue projected to hit USD 865 million by 2035. The compounded annual growth rate indicates the impact of innovation, rising healthcare needs, and increased adoption across pharmaceuticals and nutraceuticals. Strategic investments and expanding product applications further drive the market upwards. The margin between 2030 and 2035 underscores the market’s long-term viability and potential for new entrants and existing players.
US Enteric Softgel Capsules Market by Regions Share (%), 2025
The 2025 market share pie chart presents a regional breakdown of the US Enteric Softgel Capsules market. The Northeast region leads with 34%, benefiting from a high concentration of pharmaceutical manufacturing companies and research institutions. The South holds 27%, fueled by expanding nutraceutical production hubs. The Midwest captures 19%, supported by robust logistics networks, while the West accounts for 15%, spurred by innovation ecosystems and tech integration in pharma solutions. The remaining 5% falls under 'Other', representing smaller states and emerging clusters. This division reflects the regional economic strengths, healthcare infrastructure, and investment in pharma R&D shaping market dynamics for 2025.
US Enteric Softgel Capsules Recent Developments
In March 2024, Catalent, Inc. announced the launch of a new facility in Maryland dedicated to the production of advanced enteric softgel capsules. The facility integrates automation and AI-driven quality control, aiming to boost production capacity by 25%. This expansion underscores Catalent’s commitment to meeting surging demand in the pharmaceutical and biotech sectors and maintaining its leadership in innovative drug delivery systems.
In May 2024, Thermo Fisher Scientific’s Patheon division introduced a next-generation enteric softgel capsule leveraging a novel plant-based coating. This launch addresses the rising demand for vegetarian and vegan pharmaceutical formulations. By enhancing the capsules' stability and offering a clean-label solution, Patheon targets both the ethical consumer segment and companies seeking approval for green products.
In February 2024, Aenova Group formed a strategic partnership with a leading US-based nutraceutical company to co-develop enteric-coated omega-3 softgels. The collaboration intends to deliver high-bioavailability supplements tailored for consumers with sensitive gastrointestinal systems. Through this alliance, Aenova extends its expertise in innovative encapsulation technology and strengthens its foothold in the US dietary supplements market.
Press Releases